🫀🔬 New insights on #antithrombotic therapy after #bioprosthetic mitral valve replacement. What are the latest findings? How can they impact clinical practice? 📢 A new study is out in #EHJPharmacotherapy. Don’t miss it! 👉 bit.ly/4hEtKhH Felice Gragnano European Society of Cardiology Journals

🔬🩺 How does #BMI influence the kidney-protective effects of #SGLT2 inhibitors in diabetes? 📢 A nationwide study published in #EHJPharmacotherapy reveals new insights for personalized treatment strategies. Read more 👉 bit.ly/3CJRbqF Felice Gragnano European Society of Cardiology Journals

Frail persons are for sure a certain group of paetins

Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months academic.oup.com/eurheartj/arti…

The EMPAG-HF trial unveils the acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography in patients with HF

Triple lipid lowering drugs

SHould we use colchicine in patients with MI?

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy

Be where digital transformation happens. #ESCAIsummit2025 is the gateway for cutting-edge digital solutions that are shaping #cvcare From innovation to implementation – Showcase your breakthroughs and lead the change 👉 escardio.org/Congresses-Eve… Sandy Engelhardt Nico Bruining EiC EHJ Digital Health

Is albumin level associated with risk of major bleeding in patients with Afib on DOACs?

🧠💊 Is clopidogrel a *smart choice* for long-term antiplatelet monotherapy in patients with coronary artery disease? We share our perspective in our latest article in #EHJPharmacotherapy! 📖🔍 👉 academic.oup.com/ehjcvp/advance… Paolo Calabro' Vincenzo De Sio Mattia Galli EHJ-CVP Editor-in-Chief

Interesting data

Early use of SGLT2i after myocardial infarction

🆕 Long-term Antiplatelet Monotherapy after PCI: Searching for the smart choice 🔥 A new #Pharmapulse now online in #EHJPharmacotherapy 👉 ow.ly/lGzK50VOqH9 EHJ-CVP Editor-in-Chief Felice Gragnano Mattia Galli Vincenzo De Sio Paolo Calabro'

🧠 Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with AF: new data from the GLORIA-AF registry now in #EHJPharmacotherapy 👉 ow.ly/Z94Q50VOqW8 EHJ-CVP Editor-in-Chief Felice Gragnano

Looking back to our first meeting in 1949, the ESC is proud to celebrate a legacy of global members who contribute so much. 75 years of impact. 75 years of improving cardiovascular care. Explore our story: ow.ly/EAs850VWWhw #ESC75Years

#EHJ: Consensus document on vaccination as CV prevention Vaccination is not only vital for preventing infectious diseases, it is also a proven strategy to reduce the risk of heart attacks, #heartfailure, and premature #cvdeath Read our recently published evidence-based

Prevention of #AFib with SGLT2-I across the spectrum of cardiovascular disorders: a meta-analysis of RCTs 📊 🔗 academic.oup.com/ehjcvp/advance… #EHJPharmacotherapy 💊 EHJ-CVP Editor-in-Chief 👔 European Society of Cardiology European Society of Cardiology Journals 📚

Happening now: #ESCardioCRT is underway with a discussion focused on clear actions and pathways to be created for the improvement and harmonisation of #ESCGuidelines implementation at national level. Thank you to all partners present contributing to building a blueprint that

EHJ-CVP Editor-in-Chief It is a pleasure to present the journal's new Impact Factor which increased to 6.1. I would like to express my gratitude to our eminent editorial board, our reviewers, our authors and to OUP #escardio.org@esc_journals#cardiology@pharmacotherapy